<DOC>
	<DOCNO>NCT01316133</DOCNO>
	<brief_summary>This study evaluate efficacy safety tacrolimus steroid observe remission rate 24 week lupus nephritis patient non-responders steroid monotherapy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Tacrolimus With Steroid Korean Lupus Nephritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients satisfy 4 criterion diagnosis systemic lupus erythematosus ( ARA criterion , 1982 ) Patients fall WHO class IIIIV lupus nephritis renal biopsy Patients refractory lupus nephritis Proteinuria ≥ 0.5 g/day Patients take steroid ≥ 20 mg/day one month prior study Patients fail firstline therapy ( nonresponders steroid monotherapy ) Patients allergic resistant macrolide antibiotic tacrolimus Patients receive tacrolimus past ( exclude drug external use ) Patients use immunosuppressant within 4 week initiation study Patients receive systematic chemotherapy since enrollment ( local chemotherapy allow . ) Patients malignant tumor develop within recent 5 year history malignant tumor Patients severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may influence absorption tacrolimus Patients SCr ≥ 200 µ㏖/L ≥ 2.3 mg/dL Patients liver function level twice upper limit normal acute active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>FK506</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Calcineurin inhibitor</keyword>
</DOC>